CANbridge Pharmaceuticals Inc.
1228.HKHKSEHealthcareBiotechnology
Latest quote
HK$1.99
−HK$0.085 · -4.10%
1228.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteCANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzyme replacement therapy for Hunter syndrome; NERLYNX (Neratinlib), a powerful, irreversible tyrosine kinase inhibitor targeting HER2-positive breast cancer; and Caphosol Mouth Rinse, used to alleviate temporary and persistent dry mouth and throat. Its robust development pipeline features several investigational therapies: CAN008, an artificially engineered antibody-like fully human fusion protein being developed for glioblastoma multiforme; CAN108, an orally administered reversible inhibitor of the ileal bile acid transporter, designed to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 for complement-mediated conditions; CAN103 and CAN104, both recombinant human enzyme replacement therapies (ERTs); CAN105, a bispecific antibody; and gene therapy programs CAN201 and CAN202, both utilizing adeno-associated virus (AAV) sL65 capsid technology. Established in 2012, CANbridge Pharmaceuticals Inc. is based in Beijing, China.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CN
- CEO
- Qun Xue
- Listed since
- Dec 10, 2021
- Employees
- 41
Market position
Day range
Current HK$1.99
52-week range
Current HK$1.99
- Open
- HK$2.025
- Previous close
- HK$2.075
- Volume
- 556K
- 0.34× average
- Average volume
- 1.62M
- Average daily volume
- Market cap
- 845.43M HKD
- Beta
- -0.09
- Market reference 1
- 50-day average
- HK$2.0491
- -2.88% below average
- 200-day average
- HK$2.2992
- -13.45% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.09B CNY
- P/E (TTM)
- 35.99×
- P/B (TTM)
- -2.38×
- P/S (TTM)
- 14.5×
- EV / EBITDA
- -13.74×
- Earnings yield
- 1.30%
- Free cash flow yield
- -3.36%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 73.13%
- Operating margin
- -185.46%
- Net margin
- 29.65%
- Return on equity
- -4.33%
- Return on assets
- 8.96%
- Return on invested capital
- 32.86%
Financial health
- Debt / equity
- -0.05×
- Current ratio
- 0.24×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 49.98M CNY | 85.1M CNY | 102.87M CNY | 78.97M CNY | 31.16M CNY |
| Cost of goods sold | 13.43M CNY | 30.8M CNY | 38.71M CNY | 30.08M CNY | 12.39M CNY |
| Gross profit | 36.56M CNY | 54.3M CNY | 64.16M CNY | 48.89M CNY | 18.78M CNY |
| Research and development | 45.05M CNY | 251.76M CNY | 257.21M CNY | 311.17M CNY | 427.66M CNY |
| Selling, general, and administrative | 84.2M CNY | 143.06M CNY | 173.5M CNY | 195.69M CNY | 246.27M CNY |
| Operating expenses | 129.25M CNY | 394.82M CNY | 429.28M CNY | 506.86M CNY | 673.52M CNY |
| Interest income | 362.37K CNY | 508K CNY | 10.98M CNY | 3.89M CNY | 2.61M CNY |
| Interest expense | 2.17M CNY | 8.58M CNY | 8.95M CNY | 6.86M CNY | 3.08M CNY |
| Depreciation and amortization | 13.72M CNY | 11.82M CNY | 28.46M CNY | 21.98M CNY | 15.71M CNY |
| Operating income | −92.7M CNY | −340.52M CNY | −366.55M CNY | −457.97M CNY | −655.15M CNY |
| Net income | 14.82M CNY | −442.62M CNY | −378.84M CNY | −483.48M CNY | −1.08B CNY |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- 0.15
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
1228.HK peers
ETFs holding 1228.HK
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research 1228.HKresearch.disclaimer